"This analysis along with other recent data suggest P2Y12 inhibitor monotherapy is the preferred antiplatelet approach for secondary prevention and is better than aspirin."—Michael C. McDaniel, MD, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results